Daicel Corporation (TYO:4202)

Japan flag Japan · Delayed Price · Currency is JPY
1,606.00
-33.50 (-2.04%)
Mar 2, 2026, 3:30 PM JST
24.21%
Market Cap 422.48B
Revenue (ttm) 578.81B
Net Income (ttm) 41.14B
Shares Out 257.69M
EPS (ttm) 155.25
PE Ratio 10.56
Forward PE 8.82
Dividend 60.00 (3.66%)
Ex-Dividend Date Mar 30, 2026
Volume 1,270,300
Average Volume 907,245
Open 1,574.00
Previous Close 1,639.50
Day's Range 1,548.00 - 1,606.00
52-Week Range 1,057.50 - 1,658.00
Beta 0.29
RSI 68.21
Earnings Date Feb 5, 2026

About Daicel

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photo... [Read more]

Sector Materials
Founded 1919
Employees 11,178
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4202
Full Company Profile

Financial Performance

In fiscal year 2025, Daicel's revenue was 586.53 billion, an increase of 5.10% compared to the previous year's 558.06 billion. Earnings were 49.48 billion, a decrease of -11.38%.

Financial Statements

News

There is no news available yet.